2019
Implementing Data to Care-What Are the Costs for the Health Department?
Neblett Fanfair R, Shrestha RK, Randall L, Lucas C, Nichols L, Camp NM, Brady K, Jenkins H, Altice F, Villanueva M, DeMaria A. Implementing Data to Care-What Are the Costs for the Health Department? JAIDS Journal Of Acquired Immune Deficiency Syndromes 2019, 82 Suppl 1: s57-s61. PMID: 31425397, DOI: 10.1097/qai.0000000000001968.Peer-Reviewed Original Research
2011
The Cost of Integrated HIV Care and Buprenorphine/Naloxone Treatment: Results of a Cross-Site Evaluation
Schackman BR, Leff JA, Botsko M, Fiellin DA, Altice FL, Korthuis PT, Sohler N, Weiss L, Egan JE, Netherland J, Gass J, Finkelstein R. The Cost of Integrated HIV Care and Buprenorphine/Naloxone Treatment: Results of a Cross-Site Evaluation. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: s76-s82. PMID: 21317599, PMCID: PMC3270565, DOI: 10.1097/qai.0b013e31820a9a66.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxone treatmentIntegrated care patientsBuprenorphine/naloxoneNaloxone treatmentCare patientsClinic costsIntegrated careCross-site evaluationHIV clinical sitesIntegrated HIV careUrine toxicology analysisMedian monthly costPotential cost offsetsToxicology analysisHIV careIntegrated HIVSimilar patientsPhysician encountersPatient costsClinic settingMedian numberProvider encountersPatient timePatientsClinical sites
1999
Clinical Guidelines and Pharmacist Intervention Program for HIV‐Infected Patients Requiring Granulocyte Colony‐Stimulating Factor Therapy
Engles‐Horton L, Skowronski C, Mostashari F, Altice F. Clinical Guidelines and Pharmacist Intervention Program for HIV‐Infected Patients Requiring Granulocyte Colony‐Stimulating Factor Therapy. Pharmacotherapy The Journal Of Human Pharmacology And Drug Therapy 1999, 19: 356-362. PMID: 10221375, DOI: 10.1592/phco.19.4.356.30938.Peer-Reviewed Original ResearchConceptsIntervention periodPreintervention periodFactor therapyG-CSFGranulocyte colony-stimulating factor therapyHuman immunodeficiency virus (HIV) infectionColony-stimulating factor therapyPharmacist intervention programPharmacist-based interventionMean hospital stayImmunodeficiency virus infectionHospital medical information systemG-CSF dosesNumber of patientsMedical house staffTherapeutics subcommitteeHospital stayPharmacist interventionsChart reviewHospitalized patientsClinical pharmacistsImmunodeficiency syndromePatient morbidityPharmacy costsClinical guidelines